Cetera Advisors’s CorMedix CRMD Stock Holding History

Cetera Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,000	Closed	-$2K	–	962
2018 Q2	$2K	Hold	2,000	–	–	﹤0.01%	868
2018 Q1	$2K	Buy	+2,000	New	+$3.99K	﹤0.01%	778

Other funds holding CRMD

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Planning Directions Glen Mills, Pennsylvania $198M AUM 11.06% 1-Year Est. Return

Cetera Advisors's CRMD Position: Q3 2018 in Review

Cetera Advisors sold out of CorMedix (CRMD) in Q3 2018, closing a stake of 2,000 shares — an estimated $2K sold.

Cetera Advisors first reported a position in CRMD in Q1 2018 and held it in 2 quarters. The position peaked at $2K in Q2 2018. 33 funds tracked by Wall St. Rank hold CRMD as of Q3 2018.

Cetera Advisors reported no remaining CorMedix position as of Q3 2018 after selling out during the quarter.
Cetera Advisors sold 2,000 CorMedix shares in Q3 2018, an estimated $2K.
Cetera Advisors first reported a position in CorMedix in Q1 2018 and held it in 2 quarters.
Cetera Advisors's CorMedix position peaked at $2K in Q2 2018.
33 funds tracked by Wall St. Rank held CorMedix as of Q3 2018.

Based on Cetera Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.